Last reviewed · How we verify

NCT05240248: OPTIDERMAL

Optilene® Suture Material for Dermal Sutures

Completed Last updated 21 February 2024
What this trial tests

trial in Laceration in 172 participants. Completed in 23 July 2023.

Timeline
22 June 2022
Primary endpoint
23 June 2023
23 July 2023

Quick facts

Lead sponsorAesculap AG
StatusCompleted
Study typeOBSERVATIONAL
Enrollment172
Start date22 June 2022
Primary completion23 June 2023
Estimated completion23 July 2023
Sites1 location across Spain

Conditions studied

Sponsor

Aesculap AG — full company profile →

Who can join

18 and older, any sex, with Laceration or Incision. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this non-interventional study, Optilene® suture will be evaluated for skin closure in adult patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Aesculap AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05240248.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing